本帖最后由 老马 于 2012-1-13 21:20 编辑
- _" M: b% z0 P+ v
: {' z: M# R% M2 @7 t% D爱必妥和阿瓦斯丁的比较- n* b' M- L" `. ^
) s* _$ K* I5 Y9 h; e* @6 ^
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
$ s+ p4 l* S7 M
6 Y6 P& m4 k; Z: ^
0 I" u3 [" \/ H8 E- S
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
0 t% ^4 y$ n: s: d==================================================8 x+ U9 @# V/ Y A8 Z$ z7 ^# d
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
% [4 @- b5 g0 wPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.2 V- |8 R; ]" G
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
( A4 i# ]0 B! }2 \! [; v5 T1 } {
|